Showing 2371-2380 of 6036 results for "".
- Outlook Therapeutics Reports Positive Efficacy and Safety Data from Phase 3 NORSE TWO Trial of Lytenava for Wet AMDhttps://modernod.com/news/outlook-therapeutics-reports-positive-efficacy-and-safety-data-from-phase-3-norse-two-trial-of-lytenava-for-wet-amd/2479428/Outlook Therapeutics announced positive clinical and highly statistically significant topline results from its pivotal phase 3 NORSE TWO safety and efficacy trial evaluating ONS-5010/Lytenava (bevacizumab) for treatment of neovascular age-related macular degeneration (wet AMD). “We are de
- Oxurion Appoints Tom Graney, CFA, as Chief Executive Officerhttps://modernod.com/news/oxurion-appoints-tom-graney-cfa-as-chief-executive-officer/2479215/Oxurion NV announced in a planned succession, the promotion of Tom Graney, CFA, from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Patrik De Haes, MD, who after 14 years as CEO has decided to move away from day-to-day management
- Bausch Health Announces Vyzulta is Now Approved In Brazilhttps://modernod.com/news/bausch-health-announces-vyzulta-is-now-approved-in-brazil/2479084/Bausch Health Companies and Nicox announced that Vyzulta (latanoprostene bunod ophthalmic solution), 0.024%, has received regulatory approval from the Brazilian Health Regulatory Agency (ANVISA – Agência Nacional de Vigilância Sanitária). Vyzulta is indicated for the reduction of IOP in pa
- Heine Announces Launch of Omega 600 Lightweight Indirect Ophthalmoscopehttps://modernod.com/news/heine-announces-launch-of-new-omega-600-lightweight-indirect-ophthalmoscope/2478842/Heine has launched its newest indirect ophthalmoscope, the Omega 600. The Omega 600 includes a new design that makes it the lightest high-end indirect on the market courtesy of a new ultralight battery, according to Heine. Other new features are Heine’s visionBOOST technology, which is des
- Preliminary Results From Aldeyra’s Phase 3 Tranquility Trial Offer Promise for Patients With Dry Eye Syndrome, Says GlobalDatahttps://modernod.com/news/preliminary-results-from-aldeyras-phase-3-tranquility-trial-offer-promise-for-patients-with-dry-eye-syndrome-says-globaldata/2478786/Aldeyra Therapeutics recently announced topline results from the run-in cohort of the phase 3 trial evaluating reproxalap 0.25% for patients with dry eye syndrome (DES). The positive impact of the therapy on endpoints, such as ocular dryness, discomfort and Schirmer’s test, although preliminary,
- Wize Pharma Announces Positive Topline Results in Phase 4 Study of LO2A for Dry Eye in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-positive-topline-results-in-phase-4-study-of-lo2a-for-dry-eye-in-patients-with-sjogrens-syndrome/2478529/Wize Pharma reported topline results from its phase 4 clinical trial of its in-license eye drop formula, LO2A, for the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren’s syndrome. The randomized, double-masked comparative study evaluated LO2A versus Alcon̵
- Aurinia Pharmaceuticals’ Dry Eye Drug Candidate Does Not Meet Primary Endpointhttps://modernod.com/news/aurinia-announces-outcome-of-audrey-clinical-trial-in-dry-eye-syndrome/2478487/Aurinia Pharmaceuticals announced topline data from the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). The trial did not achieve statistical significance on its primary endpoint of a 10 mm or greater improvem
- Aurinia Completes Final Patient Treatment in AUDREY Phase 2/3 Clinical Trial of Voclosporin Ophthalmic Solution for Dry Eyehttps://modernod.com/news/aurinia-completes-final-patient-treatment-in-audrey-phase-2-3-clinical-trial-of-voclosporin-ophthalmic-solution-for-dry-eye/2478336/Aurinia Pharmaceuticals announced that the last patient study visit has occurred in the phase 2/3 AUDREY clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Despite the challenges posed by the ongoing viral pandemic, our c
- Aurinia Completes Patient Enrollment In Phase 2/3 Trial of Voclosporin for the Treatment of Dry Eyehttps://modernod.com/news/aurinia-completes-patient-enrollment-in-phase-2-3-trial-of-voclosporin-for-the-treatment-of-dry-eye/2477914/Aurinia Pharmaceuticals announced it has completed enrollment for the phase 2/3 AUDREY clinical trial evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES). “Voclosporin’s proven mechanism of action as a novel calcineurin inhibitor gives us
- Oxurion NV to Provide Business and Clinical Update at AAO and OIS Meetings in San Franciscohttps://modernod.com/news/oxurion-nv-to-provide-business-and-clinical-update-at-aao-and-ois-meetings-in-san-francisco/2476969/Oxurion NV announces that the company will be providing a business and clinical update at the American Academy of Ophthalmology’s annual meeting (AAO) and Ophthalmology Innovation Summit (OIS@AAO) in San Francisco. Patrik De Haes, MD, CEO of Oxurion will be presenting the company’s b